If we heard news of DOE and positron talking this would be trading much higher. It's hard to believe they are not talking because positron has the potential to take over for the DOE, must I remind you, the DOE is looking to get out of nuclear medicine they want a company to take it over, I would bet my bottom dollar they are working the DOE weekly if not daily IMO.
I disagree that SR-82 revenue will be a year away. In the USA that is probably true, but not for generators for use in Canada & Europe. Sales could start in early 2013, if not sooner. The generator is approved in Canada, and the EMA has issued waivers and deferrals for the purpose of this study.
In Canada, where Draximage's Ruby-Fill is involved in a non-regulatory PET vs. SPECT study that will last 2 years, involve up to 10 medical centers, and has an enrollment of 6,000 patients.
Estimated Study Completion Date:________June 2014 Estimated Primary Completion Date:________October 2013 (Final data collection date for primary outcome measure)
In Europe, Draximage is involved with another study which is scheduled to conclude by June 2014. Scope of the application Active substance(s): Rubidium (82Rb) chloride Condition(s): Visualization of myocardial perfusion for diagnostic purposes Pharmaceutical form(s): Radionuclide generator Route(s) of administration: Intravenous use Name/corporate name of the PIP applicant: Jubilant DraxImage Inc.
Market Data 
Markets 
AI
